317 related articles for article (PubMed ID: 31081046)
21. Targeting the ABC transporter ABCB5 sensitizes glioblastoma to temozolomide-induced apoptosis through a cell-cycle checkpoint regulation mechanism.
Lee CAA; Banerjee P; Wilson BJ; Wu S; Guo Q; Berg G; Karpova S; Mishra A; Lian JW; Tran J; Emmerich M; Murphy GF; Frank MH; Frank NY
J Biol Chem; 2020 May; 295(22):7774-7788. PubMed ID: 32317280
[TBL] [Abstract][Full Text] [Related]
22. IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide.
Ramcharan R; Aleksic T; Kamdoum WP; Gao S; Pfister SX; Tanner J; Bridges E; Asher R; Watson AJ; Margison GP; Woodcock M; Repapi E; Li JL; Middleton MR; Macaulay VM
Oncotarget; 2015 Nov; 6(37):39877-90. PubMed ID: 26497996
[TBL] [Abstract][Full Text] [Related]
23. Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells.
Banelli B; Daga A; Forlani A; Allemanni G; Marubbi D; Pistillo MP; Profumo A; Romani M
Oncotarget; 2017 May; 8(21):34896-34910. PubMed ID: 28432280
[TBL] [Abstract][Full Text] [Related]
24. Inability of p53-reactivating compounds Nutlin-3 and RITA to overcome p53 resistance in tumor cells deficient in p53Ser46 phosphorylation.
Ma T; Yamada S; Ichwan SJ; Iseki S; Ohtani K; Otsu M; Ikeda MA
Biochem Biophys Res Commun; 2012 Jan; 417(3):931-7. PubMed ID: 22166212
[TBL] [Abstract][Full Text] [Related]
25. Isofuranodiene synergizes with temozolomide in inducing glioma cells death.
Brunetti A; Marinelli O; Morelli MB; Iannarelli R; Amantini C; Russotti D; Santoni G; Maggi F; Nabissi M
Phytomedicine; 2019 Jan; 52():51-59. PubMed ID: 30599912
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression.
Yu Z; Chen Y; Wang S; Li P; Zhou G; Yuan Y
Cancer Lett; 2018 Aug; 428():77-89. PubMed ID: 29705182
[TBL] [Abstract][Full Text] [Related]
27. RITA displays anti-tumor activity in medulloblastomas independent of TP53 status.
Gottlieb A; Althoff K; Grunewald L; Thor T; Odersky A; Schulte M; Deubzer HE; Heukamp L; Eggert A; Schramm A; Schulte JH; Künkele A
Oncotarget; 2017 Apr; 8(17):27882-27891. PubMed ID: 28427187
[TBL] [Abstract][Full Text] [Related]
28. Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA.
Zhao CY; Grinkevich VV; Nikulenkov F; Bao W; Selivanova G
Cell Cycle; 2010 May; 9(9):1847-55. PubMed ID: 20436301
[TBL] [Abstract][Full Text] [Related]
29. Dehydroepiandrosterone Induces Temozolomide Resistance Through Modulating Phosphorylation and Acetylation of Sp1 in Glioblastoma.
Yang WB; Chuang JY; Ko CY; Chang WC; Hsu TI
Mol Neurobiol; 2019 Apr; 56(4):2301-2313. PubMed ID: 30022431
[TBL] [Abstract][Full Text] [Related]
30. A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation.
Chen X; Tai L; Gao J; Qian J; Zhang M; Li B; Xie C; Lu L; Lu W; Lu W
J Control Release; 2015 Nov; 218():29-35. PubMed ID: 26428461
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
[TBL] [Abstract][Full Text] [Related]
32. The SIAH1-HIPK2-p53ser46 Damage Response Pathway is Involved in Temozolomide-Induced Glioblastoma Cell Death.
He Y; Roos WP; Wu Q; Hofmann TG; Kaina B
Mol Cancer Res; 2019 May; 17(5):1129-1141. PubMed ID: 30796178
[TBL] [Abstract][Full Text] [Related]
33. Tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cells.
Castro-Gamero AM; Borges KS; Moreno DA; Suazo VK; Fujinami MM; de Paula Gomes Queiroz R; de Oliveira HF; Carlotti CG; Scrideli CA; Tone LG
Invest New Drugs; 2013 Aug; 31(4):858-70. PubMed ID: 23299390
[TBL] [Abstract][Full Text] [Related]
34. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.
Miyachi M; Kakazu N; Yagyu S; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H
Clin Cancer Res; 2009 Jun; 15(12):4077-84. PubMed ID: 19509161
[TBL] [Abstract][Full Text] [Related]
35. Cedrol suppresses glioblastoma progression by triggering DNA damage and blocking nuclear translocation of the androgen receptor.
Chang KF; Huang XF; Chang JT; Huang YC; Weng JC; Tsai NM
Cancer Lett; 2020 Dec; 495():180-190. PubMed ID: 32987140
[TBL] [Abstract][Full Text] [Related]
36. HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA.
Rinaldo C; Prodosmo A; Siepi F; Moncada A; Sacchi A; Selivanova G; Soddu S
Cancer Res; 2009 Aug; 69(15):6241-8. PubMed ID: 19638586
[TBL] [Abstract][Full Text] [Related]
37. Thioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide.
Johannessen TC; Hasan-Olive MM; Zhu H; Denisova O; Grudic A; Latif MA; Saed H; Varughese JK; Røsland GV; Yang N; Sundstrøm T; Nordal A; Tronstad KJ; Wang J; Lund-Johansen M; Simonsen A; Janji B; Westermarck J; Bjerkvig R; Prestegarden L
Int J Cancer; 2019 Apr; 144(7):1735-1745. PubMed ID: 30289977
[TBL] [Abstract][Full Text] [Related]
38. LQB‑118 compound inhibits migration and induces cell death in glioblastoma cells.
Bernardo PS; Guimarães GHC; De Faria FCC; Longo GMDC; Lopes GPF; Netto CD; Costa PRR; Maia RC
Oncol Rep; 2020 Jan; 43(1):346-357. PubMed ID: 31746438
[TBL] [Abstract][Full Text] [Related]
39. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
40. Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines.
Rubner Y; Muth C; Strnad A; Derer A; Sieber R; Buslei R; Frey B; Fietkau R; Gaipl US
Radiat Oncol; 2014 Mar; 9(1):89. PubMed ID: 24678590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
